相关实验视频
Updated: Jan 10, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
885
在2型糖尿病和肥胖症中Orforglipron:概述
Theodoros Panou1, Evanthia Gouveri1, Djordje S Popovic2,3
1Diabetes Centre-Diabetic Foot Clinic, Second Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece.
Expert review of clinical pharmacology
|November 23, 2025
概括
甲福格利是一种口服葡萄糖类-1受体激动剂 (GLP-1RA),在治疗2型糖尿病和肥胖症方面表现出显著的疗效. 虽然有效控制血糖和体重,但由于潜在的胃肠道副作用,建议谨慎使用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
背景情况:
- 类似葡萄糖-1受体激动剂 (GLP-1RAs) 是已确立的2型糖尿病 (T2DM) 和肥胖症的治疗方法.
- 寻求新型治疗剂以改善患者的治疗结果和患者的坚持.
研究的目的:
- 评估Orforglipron的疗效和安全性,这是一种新的口服非基 GLP-1RA.
- 为了比较orforglipron的有效性与现有的GLP-1RAs用于T2DM和肥胖管理.
主要方法:
- 在Scopus,PubMed/MEDLINE和谷歌学者中进行了电子文献搜索.
- 用数据合成和元分析来评估治疗结果.
主要成果:
- 在T2DM患者中,Orforglipron显著降低了HbA1c (高达2.10%) 和体重 (高达10.1公斤).
- 在超重/肥胖研究中,观察到体重减轻高达13.0公斤,在元分析中,格利是减肥最有效的GLP-1RA.
- 系统性血压也显著下降. 报告有轻度至中度的恶心和吐,特别是在较高剂量时.
结论:
- 在T2DM和肥胖症中,Orforglipron是一种有前途的口服治疗选择,可显著降低葡萄糖和体重.
- 建议谨慎定位剂量以减轻恶心和吐等不良事件.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Carbohydrate Metabolism
13.7K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
13.7K
Oral Hypoglycemic Agents: Biguanides and Glitazones
567
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
567
Glucagon-like Receptor Agonists
824
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
824
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
228
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
228
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K

